Open Access

An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model

Contributed equally
Molecular Pain20139:29

https://doi.org/10.1186/1744-8069-9-29

Received: 15 April 2013

Accepted: 12 June 2013

Published: 17 June 2013

Abstract

Background

We previously reported that nerve injury-induced neuropathic pain is initiated by newly produced lysophosphatidic acid (LPA).

Results

In this study, we developed a quantitative mass spectrometry for detecting LPA species by using Phos-tag. Following nerve injury, the levels of 18:1, 16:0 and 18:0 LPA in the spinal dorsal horn significantly increased at 3 h and declined at 6 h. Among them, 18:1 LPA level was the most abundant. In the same preparation, there were significant elevations in the activities of cytosolic phospholipase A2 (cPLA2) and calcium-independent phospholipase A2 (iPLA2), key enzymes for LPA synthesis, at 1 h, while there was no significant change in phospholipase A1 activity. Pharmacological studies revealed that NMDA and neurokinin 1 receptors, cPLA2, iPLA2 and microglial activation, as well as LPA1 and LPA3 receptors were all involved in the nerve injury-induced LPA production, and underlying cPLA2 and iPLA2 activations. In the cells expressing LPA1 or LPA3 receptor, the receptor-mediated calcium mobilization was most potent with 18:1 LPA, compared with 16:0 or 18:0 LPA. Moreover, the intrathecal injection of 18:1 LPA, but not 16:0 or 18:0 LPA, caused a spinal LPA production and neuropathic pain-like behavior.

Conclusion

These results suggest that 18:1 LPA is the predominant ligand responsible for LPA1 and LPA3 receptors-mediated amplification of LPA production through microglial activation.

Keywords

Lysophosphatidic acid Neuropathic pain MALDI-TOFMS Phos-tag Cytosolic phospholipase A2 Neuron

Background

Lysophosphatidic acid (LPA) is a lysophospholipid with a structure comprising a glycerol backbone, a free phosphate group, and a single fatty acyl chain. Usually, LPA consists of several molecular species with different acyl chains varing in the sn-1 or sn-2 position, the length and degree of saturation [1, 2]. LPA is an important biological signaling molecule, which is generated in several biological fluids such as serum, saliva and follicular fluid [35], and in most tissues such as brain, spinal cord and lung [6, 7]. Its landmark roles in various physiological and pathophysiological conditions, including wound healing, lung fibrosis, cancer, reproduction, and hair growth, have been well-documented [812]. These biological functions have been identified to link with specific G-protein coupled receptors named LPA1-6[13, 14].

In recent decade, LPA has gained special attention because of its emerging role as an important risk factor in chronic neuropathic pain [1518]. In these studies, we found the roles of LPA1 signaling for the initiation of neuropathic pain and its underlying mechanisms, such as demyelination [1924]. Among these reports, it should be noted that the single intrathecal (i.t.) injection of LPA mimicked the behavioral changes, demyelination and several biochemical changes caused by nerve injury [20, 23, 25]. This unique approach to study neuropathic pain and its mechanisms was further confirmed by other groups [2628]. Emerging findings were observed with the studies of biosynthesis of LPA in the spinal cord or dorsal root in the neuropathic pain model. The LPA production, measured by biological assay, reached a maximum at 3 h after the injury [6], being consistent with the pharmacological study that the blockade of neuropathic pain was critically observed when LPA1 receptor antagonist was treated within 2 – 4 h, but not at 6 h [21]. Similar LPA production was also found with i.t. LPA treatment [29], suggesting that LPA itself plays important roles in the amplification of LPA biosynthesis. Interestingly, LPA-induced amplification of LPA production was abolished in Lpar3-deficient (Lpar3 -/- ) mice [29], indicating the involvement of LPA3 receptor. Moreover, it should be noted that microglial activation was also involved in this LPA production [30].

On the other hand, we successfully identified the species of lysophosphatidylcholine (LPC), the precursor of LPA, in the spinal dorsal horn after the nerve injury [31]. In this experiment, the LPC species were simultaneously determined by use of nanostructure-assisted laser desorption/ionization time-of-flight mass spectrometry system, which removed the need to add chemical matrices for the analysis of small molecules, and enabled to minimize their background noises [32]. However, it was difficult to quantitate or even detect any species of LPA by this system, because of poor ionization due to its acidic nature and multiple signals derived from free and salt forms. Recently, this problem was solved by derivatization of LPA molecules using a phosphate-capture molecule, Phos-tag [33], followed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOFMS) system [7].

In the present study, we attempted to measure the LPA production in the spinal dorsal horn following sciatic nerve injury by use of this LPA derivatization methodology, and identified the key species of LPA in charge of amplification of LPA production.

Results

Determination of LPA by MALDI-TOFMS using Phos-tag

To detect LPA species, in this study, we developed a quantitative MALDI-TOFMS method by use of a phosphate-capture molecule, Phos-tag, according to previous reports [7, 33, 34]. Figure 1a and b present the MALDI-TOF mass spectrum of internal standard 17:0 LPA, as well as mixture of authentic standard reagents 16:0, 18:0 and 18:1 LPA with the internal standard at the level of 0.2 nmol, respectively. Distinctive peaks were detected at m/z 1011, 997, 1023 and 1025, which correspond to 17:0 LPA-Phos-tag, 16:0 LPA-Phos-tag, 18:1 LPA-Phos-tag and 18:0 LPA-Phos-tag, respectively (Figure 1a and b).
Figure 1

Biosynthesis of LPA following nerve injury by MALDI-TOFMS using Phos-tag. (a and b) Representative charts of mass spectra with internal standard 17:0 LPA (panela ), and mixed standard reagents 16:0, 18:0 and 18:1 LPA as well as internal control (panelb ) at the level of 0.2 nmol, following the use of Phos-tag. (c  and d) Mass spectra of LPA extracts from the contralateral (panelc ) and ipsilateral (paneld ) dorsal half of spinal cord at 3 h after nerve injury. “UI” represents the unidentified compound. (e) Levels of produced LPA species (18:1, 16:0, 18:0 LPA) in spinal cord preparations of control or injured mice. The capital letter “C” represents the control group (naive mice). Data represent means ± SEM from experiments using 3-8 mice. *p < 0.05, versus with the control group.

In order to quantify the levels of these LPA species, we applied each standard LPA (16:0, 18:0 and 18:1 LPA) at 0, 0.1, 0.2, 0.5, 1.0 and 2.0 nmol with 17:0 LPA at 0.2 nmol into MALDI-TOFMS system. According to the ratios of ion-peak intensities with each standard LPA to that with 17:0 LPA, the concentration-related linear equations were established after subtracting the basal background. They were defined as y = 0.9928x (R2 = 0.9975; x: concentration ratio of 16:0 to 17:0 LPA, y: intensity ratio of 16:0 to 17:0 LPA), y = 1.4122x (R2 = 0.9923; x: concentration ratio of 18:0 to 17:0 LPA, y: intensity ratio of 18:0 to 17:0 LPA) and y = 0.3956x (R2 = 0.9971; x: concentration ratio of 18:1 to 17:0 LPA, y: intensity ratio of 18:1 to 17:0 LPA), responding to 16:0, 18:0 and 18:1 LPA, respectively. In subsequent studies, LPA equivalents in the extracts from solid tissue were estimated using these equations based on linear LPA concentration-dependent responses.

Time-related elevation of nerve injury-induced LPA production

We analyzed LPA levels in the spinal dorsal horn after nerve injury by the MALDI-TOFMS system. As shown in the representative mass spectra of contralateral (control side) and ipsilateral (injured side) spinal dorsal horn at 3 h after nerve injury (Figure 1c and d), marked increases of the ion-signal were observed at m/z 997, 1023 and 1025 in the ipsilateral spinal cord, corresponding to 16:0, 18:1 and 18:0 LPA, respectively.

LPA equivalents were calculated based on the linear equations of each LPA. As shown in Figure 1e, after nerve injury, the 18:1 LPA level peaked at 3 h, followed by the slight decline at 6 h. Quite similar changes were also observed in the 16:0 and 18:0 LPA production (Figure 1e).

Blockade of nerve injury-induced LPA production

Nerve injury causes the release of pain transmitters such as glutamate (Glu) and substance P (SP) from primary afferent fibers, and they activate NMDA and neurokinin 1 (NK1) receptors at the dorsal horn, respectively [18]. Although their roles in neuropathic pain are well known, the extent of their contribution to LPA production remains unclear. Here, we injected MK-801 or CP-99994 (10 nmol, i.t.), the antagonists of NMDA or NK1 receptor, respectively [35], at 30 min prior to nerve injury, and found that both of them significantly blocked nerve injury-induced LPA production with three species at 3 h (Figure 2a).
Figure 2

Blockade of nerve injury-induced LPA production. (a) Following pre-treatments of vehicle, MK-801, CP-99994, AACOCF3, BEL (each 10 nmol, i.t.) and minocycline (30 mg/ml, i.p.) before nerve injury, the ipsilateral spinal dorsal horn of each mouse was isolated at 3 h after injury. Levels of LPA species (18:1, 16:0, 18:0 LPA) were measured using such spinal cord preparations by MALDI-TOFMS. Besides, Lpar1- and Lpar3-deficient mice were also used to evaluate the LPA production at 3 h after injury. The capital letter “C” represents the control group (naive mice). The “veh”, “MK”, “CP”, “AA” and “mino” represent vehicle, MK-801, CP-99994, AACOCF3 and minocycline, respectively. (b) RT-PCR experiment was carried out to evaluate the expressions of LPA1 and LPA3 receptors in cultured mouse microglia and mouse spinal dorsal horn. (c) Thermal paw withdrawal test was performed at time-course points after nerve injury using wild-type or Lpar3-deficient mice. Results represent the threshold of latency (s) to thermal stimulus. “WT” represents the wide-type mice. Data represent means ± SEM from experiments using 3-8 mice. *p < 0.05, versus with the control group; #p < 0.05, versus with the vehicle-injury or injury-WT group.

Since cytosolic phospholipase A2 (cPLA2) and calcium-independent phospholipase A2 (iPLA2) catalyze phosphatidylcholine (PC) conversion to LPC [3537], in this study, we pre-treated arachidonyl trifluoromethyl ketone (AACOCF3; 10 nmol, i.t.), a mixed inhibitor of cPLA2 and iPLA2[38, 39], or bromoenol lactone (BEL; 10 nmol, i.t.), a specific iPLA2 inhibitor [38], at 30 min before nerve injury. As shown in Figure 2a, both inhibitors abolished the nerve injury-induced LPA production (Figure 2a).

Similarly, minocycline [30 mg/kg, intraperitoneal (i.p.)], a microglial activation antagonist [30], completely blocked injury-induced LPA production (Figure 2a), when it was pre-treated twice at 1 day and 30 min before injury. In addition, reverse transcription polymerase chain reaction (RT-PCR) experiments showed that both LPA1 and LPA3 receptors are expressed in cultured mouse microglia and mouse spinal dorsal horn (Figure 2b). Nociceptive tests demonstrated that Lpar3 -/- mice completely abolished the nerve injury-induced thermal hyperalgesia (Figure 2c). Considering the fact that Lpar1-deficient (Lpar1 -/- ) mice also showed no neuropathic pain behavior and underlying mechanisms [20, 29], we attempted to see whether the injury-induced LPA production was affected in Lpar1 -/- mice, as well as in Lpar3 -/- mice. As shown in Figure 2a, the LPA levels at 3 h after injury were also abolished in mice deficient of either gene, compared with wild-type mice.

Blockades of elevated nerve injury-induced cPLA2 and iPLA2 activities

In this study, the nerve injury-induced activations of cPLA2 and iPLA2 in the spinal dorsal horn were evaluated by cPLA2 and iPLA2 activity assays. The enzyme activity of cPLA2 was maximal at 1 h, and slowly declined to the control level at 3 h (Figure 3a). Although the maximal activity of iPLA2 was also observed at 1 h, the decline was rapid (Figure 3b). The enhanced cPLA2 activity was abolished by MK-801, CP-99994, AACOCF3 or BEL (each 10 nmol, i.t.), all of which had been pretreated 30 min before the nerve injury. The pretreatments of minocycline (30 mg/kg, i.p.) 1 day and 30 min before the injury also abolished the enhanced cPLA2 activity (Figure 3c). All these inhibitors also significantly inhibited the enhanced iPLA2 activity, though their sensitivities against iPLA2 were varied among inhibitors and different from those against cPLA2 (Figure 3d). Among them, it was noted that MK-801-induced inhibition of iPLA2 was partial, while BEL inhibited the activity to the level lower than the uninjured control. Similar complete blockade was observed in Lpar1 -/- or Lpar3 -/- mice (Figure 3e and f). However, as shown in Figure 3g, there was no significant change in phospholipase A1 (PLA1) activity after nerve injury.
Figure 3

Blockade of nerve injury-induced cPLA 2 and iPLA 2 activations. (a and b) Activation of spinal cPLA2 (panela ) and iPLA2 (panelb ) were detected by cPLA2 and iPLA2 activity assays at defined time points after nerve injury. The capital letter “C” represents the control group (naive mice). (c and d) After pre-treatments of vehicle, MK-801, CP-99994, AACOCF3, BEL (each 10 nmol, i.t.) and minocycline (30 mg/ml, i.p.) before nerve injury, the activities of spinal cPLA2 (panelc ) and iPLA2 (paneld ) at 1 h after injury were evaluated. The “veh”, “MK”, “CP”, “AA” and “mino” represent vehicle, MK-801, CP-99994, AACOCF3 and minocycline, respectively. (e and f) Activities of cPLA2(panele ) and iPLA2 (panelf ) were measured at 1 h after injury using the Lpar1- and Lpar3-deficient mice. “WT” represents the wide-type mice. (g) PLA1 activity in the spinal dorsal horn was measured by PLA1 activity assay at time-course points after nerve injury. Data represent means ± SEM from experiments using 3-6 mice. *p < 0.05, versus with the control group; #p < 0.05, versus with the vehicle/WT-injury group.

Cell-type identification of activated cPLA2 in spinal cord

In order to identify the cell-type expressing activated (phosphorylated) cPLA2 (p-cPLA2) in the spinal cord, we performed double immunostaining of p-cPLA2 with antibodies against two kinds of cell-specific markers: neuronal nuclei (NeuN; neuron) and ionized calcium-binding adaptor molecule 1 (Iba1; microglia). At 1 h after nerve injury, most of p-cPLA2 signals co-localized with NeuN-positive neurons (Figure 4a-c), whose distributions were diffused expressed throughout laminae I-IV layers of the spinal dorsal horn (Figure 4g and h). On the other hand, a few signals were also observed in Iba1-positive microglia (Figure 4d-f). However, there was no p-cPLA2 signal in glial fibrillary acidic protein (astrocyte marker)-positive cells (data were not shown).
Figure 4

Cell-type identification of activated cPLA 2 in spinal cord. (a-f) Immunohistochemical double labeling of p-cPLA2 (green) and NeuN (red) as well as p-cPLA2 (green) and Iba1 (red) in the spinal cord at 1 h after nerve injury. White arrows represent NeuN- or Iba1-co-localized p-cPLA2 signals. (g) Low magnification of double immunostaining with p-cPLA2 (green) and NeuN (red) in the spinal cord at 1 h after injury. (h) Diagram of Figure 4g. Red dots represent NeuN co-localized p-cPLA2 signals. Scale bar (including high and low magnifications), 50 μm.

Pharmacological blockade of nerve injury-induced cPLA2 phosphorylation

Double immunostaining with antibodies against p-cPLA2 and NeuN was performed in the spinal cord of control and pharmacological antagonists-pretreated injured mice. In control group (naive mice), p-cPLA2 showed a low expression in neurons. However, nerve injury induced a significant increase in neuronal p-cPLA2 signals at 1 h after injury, and the increase was blocked by various inhibitors, such as MK-801, CP-99994, AACOCF3, BEL and minocycline, as well as in Lpar1 -/- and Lpar3 -/- mice (Figure 5). These findings were in good accordance with those observed in experiments of LPA detection and cPLA2 and iPLA2 activity assays.
Figure 5

Blockade of p-cPLA 2 signals in spinal neurons after nerve injury. (a-i) Vehicle, MK-801, CP-99994, AACOCF3, BEL (each 10 nmol, i.t.) and minocycline (30 mg/ml, i.p.) were pre-treated before nerve injury, and the spinal cord were collected at 1 h after injury, which were used for the double immunohistochemistry with p-cPLA2 (green) and NeuN (red). Control as well as Lpar1- and Lpar3-deficient mice were also used in this experiment. White arrows represent NeuN-co-localized p-cPLA2 signals. The capital letter “C” and “I” represent control and nerve injury, respectively. The “veh”, “MK”, “CP”, “AA” and “mino” represent vehicle, MK-801, CP-99994, AACOCF3 and minocycline, respectively. Scale bar, 50 μm.

Comparison of LPA1 or LPA3 agonist activities by different species of LPA

In order to evaluate the agonist potency of each LPA species, calcium mobilization assay was performed using B103 cells expressing LPA1 or LPA3 receptor (LPA1-B103 or LPA3- B103 cells), because both LPA1 and LPA3 receptors enable to induce calcium release from intracellular stores by activating Gq/11-PLCβ-IP3 pathway. As seen in Figure 6a, when 18:1 LPA at 1-10 μM was added into the LPA1-B103 cells, a transient increase of cytosolic calcium was immediately observed, with a maximum at around 30 s after addition, followed by a gradual decline. Obvious concentration-dependent calcium mobilizations were observed in the range of 3 to 300 nM of 18:1 LPA. The half-maximal effective dose (ED50) for 18:1 LPA-induced calcium mobilization in LPA1-B103 cells was calculated as 39.2 nM (Figure 6a). As shown in Figure 6a-e, similar ED50 (20.8 nM) was also observed with 20:4 LPA, but little higher values were with 16:0 and 14:0 LPA (146.3 and 167.8 nM, respectively). When the maximal effect of 18:1 LPA was evaluated as 100%, these values of 20:4, 16:0 and 14:0 LPA were 103.2, 86.7 and 88.6%, respectively. However, as no evident maximal effect was obtained with 18:0 LPA in the range of concentrations we used, its ED50 value was not determined. Similar results were also observed in the cases with 18:1 and 20:4 LPA on LPA3-B103 cells (Figure 6f and g). The values of ED50 were 272.3 and 148.3 nM, respectively, and maximal responses were 100% and 97.8%, respectively. Compared with these two species of LPA, the calcium mobilization by 16:0, 18:0 and 14:0 LPA was so weak that their values of ED50 and maximal responses were not determined (Figure 6h-j).
Figure 6

LPA 1 or LPA 3 receptor-mediated calcium mobilization by exogenous LPA species. After the addition of 18:1 (panela  andf ), 20:4 (panelb  andg), 16:0 (panelc  andh ), 18:0 (paneld  andi ) or 14:0 (panele  andj ) LPA with defined concentrations (3, 10, 30, 100, 300 nM and 1, 3, 10 μM) into the B103 cells expressing LPA1 or LPA3 receptor, calcium mobilization assay was immediately performed. “ED50” and “Max resp” represent the half-maximal effective dose and maximal response, respectively.

Measurement of amplified LPA production by exogenous LPA injection

We previously demonstrated that i.t. LPA injection enabled to feed-forward amplify LPA [29]. In order to identify the key species of LPA molecule in charge of LPA amplification, we i.t. injected three species of LPA (18:1, 16:0 and 18:0 LPA), which were produced by nerve injury, and evaluated amplified LPA production by use of MALDI-TOFMS system. As shown in Figure 7a, after 18:1 LPA injection at 1 nmol, 18:1 LPA itself was newly produced, and the level immediately increased (indicated as 0 h). The elevation may be attributed to the sum of the basal and injected 18:1 LPA. Subsequently, the progressive increase in the level of 18:1 LPA was observed at 1 h, reached a maximum at 3 h, and slightly declined at 6 h. Besides 18:1 LPA, 16:0 and 18:0 LPA were also newly produced after 18:1 LPA injection. The levels of these species of LPA were significantly increased at 1 and 3 h, and slightly decreased at 6 h (Figure 7a). On the other hand, the i.t. administration of 16:0 or 18:0 LPA at a high dose of 10 nmol failed to produce any LPA production at 3 h (Figure 7b). Similarly, in the nociceptive behavior experiments, 18:1 LPA injection with 1 nmol induced neuropathic pain-like thermal hyperalgesia, but 16:0 or 18:0 LPA with 10 nmol did not (Figure 7c).
Figure 7

Amplification of LPA production by injection of LPA species. (a) Levels of LPA species (18:1, 16:0 and 18:0 LPA) in the spinal dorsal horn were measured by MALDI-TOFMS system at time-course points after i.t. 18:1 LPA injection with 1 nmol. (b) Measurements of LPA species were performed at 3 h after 16:0 or 18:0 LPA injection with 10 nmol. The capital letter “C” represents the control group (naive mice). (c) After i.t. injection of 18:1 LPA (1 nmol), 16:0 LPA (10 nmol) or 18:0 LPA (10 nmol), the pain behavior was evaluated by thermal paw withdrawal test. Results represent the threshold of latency (s) to thermal stimulus. Data represent means ± SEM from experiments using 3-7 mice. *p < 0.05, versus with the control/vehicle group; #p < 0.05, versus with the 0 h-LPA group.

Discussion

This study demonstrates three major findings for the first time. First, LPA with three species (18:1, 16:0 and 18:0 LPA) were produced after nerve injury with the use of MALDI-TOFMS system. Second, p-cPLA2-expressed neuron was the potent cell to release LPA through LPA1 and LPA3 receptors-mediated microglial activation. Third, 18:1 LPA was a key ligand to induce amplification of LPA production in the peripheral neuropathic pain model.

The present study successfully detected and quantified several species of LPA molecules after nerve injury through MALDI-TOFMS system with the use of Phos-tag, a zinc complex that specifically binds to a phosphate group [7, 33, 34]. This MS analysis using Phos-tag significantly decreased the detection limit of LPA compared with previous methods without Phos-tag [7, 34]. Moreover, this technique improved our previous biological titration method, because previous one depended solely on the activity of LPA1[6, 29, 35], but not LPA3 receptor, which was the important determinant of LPA synthesis [29]. Here, we found that three species of LPA, including 18:1, 16:0 and 18:0 LPA, were maximally produced in the ipsilateral side of spinal dorsal horn, but not the contralateral side, at 3 h after injury, followed by a decline at 6 h. The time-course changes of LPA production was in agreement with previous LPA measurements [6]. This data firstly provided the chemical identification of produced LPA after nerve injury, which was consistent with the molecular species composition of produced LPC (18:1, 16:0 and 18:0 LPC) [31]. Moreover, the quantitative levels of peak 18:1 LPA was approximately three- or four-folds than that of 16:0 or 18:0 LPA, respectively, suggesting that 18:1 LPA was the predominant molecular specie of spinal LPA production after nerve injury. However, there was an interesting finding that in previous LPC measurements, the amount of produced 18:1 LPC was equivalent to or slightly lower than that of 16:0 and 18:0 LPC at 75 min after nerve injury [31]. The difference may be attributed to the biochemical fact that autotaxin, an enzyme to catalyze LPC conversion to LPA, has the preferential affinity to 18:1 LPC than to 16:0 and 18:0 LPC [40].

In this study, pharmacological antagonist of NMDA or NK1 receptor (MK-801 or CP-99994, respectively) completely blocked the nerve injury-induced LPA production. Considering the fact that combination treatments of SP and Glu (or NMDA), but not single treatment, in vitro induced LPA production in spinal cord slices [35], we believed that simultaneous intense stimulation of NMDA and NK1 receptors was essential for new LPA biosynthesis in the spinal cord. This proposition was supported by the ex vivo study that capsaicin-induced LPA production in spinal cord slices was completely blocked by MK-801 or CP-99994 [35].

Additionally, both cPLA2 and iPLA2 were maximally activated at 1 h after injury, being consistent with the time point of LPA production at 3 h, because cPLA2 and iPLA2 mediate PC hydrolysis into LPC, the precursor of LPA [3537]. It should be noted that activated cPLA2 slowly reduced to the basal level from 3 h, while iPLA2 activity rapidly decreased from 2 h. The difference might be due to the distinct mechanisms of cPLA2 and iPLA2 activation, since cPLA2 can be activated by enhanced level of intracellular calcium, as seen in the calcium influx through NMDA receptor and calcium mobilization from endoplasmic reticulum mediated by NK1 receptor, while calcium-independent iPLA2 lacks the multiple triggers [18]. Moreover, it was interesting that MK-801, the antagonist of NMDA receptor, completely reversed the increased cPLA2 activity, but partially inhibited iPLA2 activity, which might be explained by the fact that the activity of cPLA2, but not iPLA2, is calcium-dependent. Furthermore, as BEL is a specific inhibitor of iPLA2 with high potency (half-maximal inhibitory concentration: 60 nM) [38], in this study, it even decreased the elevated iPLA2 activity to the level lower than the basal one. In addition, pharmacological blockade of cPLA2 or iPLA2 abolished nerve injury-induced cPLA2 and iPLA2 activations as well as LPA production.

Usually, saturated fatty acyl chains (16:0 and 18:0) are located in sn-1 position in phospholipids, while unsaturated ones (18:1) are in sn-2 position. However, there is a report that several PC molecules possess 18:1-chains in both sn-1 and sn-2 positions, such as diacyl-18:1/22:6, diacyl-18:1/20:4, diacyl-16:0/18:1 and diacyl-18:0/18:1, in the spinal cord [41]. In this study, we found there was no significant change in PLA1 activity after nerve injury. Therefore, it is suggested that the production of 18:1 LPA isoform is mainly generated by the action of PLA2, but not PLA1, and 18:1-fatty acyl chain is located in sn-1 position.

On the other hand, in this study, minocycline-induced blockade of microglial activation at early phase significantly inhibited nerve injury-induced LPA production and increased PLA2 activations, which confirmed the evidence that microglia plays important roles in LPA production. Indeed, previous study showed that both nerve injury and i.t. LPA injection induced phosphorylation of microglial p38 kinase, subsequent up-regulation of microglial activation-related gene and morphological change from ramified to amoeboid type [30].

Although the biomarker of activated iPLA2 is not available so far, we performed immunohistochemistry study to evaluate the cell-type expressing p-cPLA2 (activated cPLA2). It should be noted that p-cPLA2 was predominantly expressed in most of spinal neurons, with minor ones in microglia. The neuron-colocalized p-cPLA2 seemed to diffuse in slightly broader regions (mainly laminae I-IV) of spinal dorsal horn. This broader distribution was similar to the case with activated microglia after the nerve injury [30]. Moreover, since most of p-cPLA2-expressing neurons were observed in broader regions of dorsal horn, but not in line-up regions at superficial layers (lamina I-II), we speculated that the neurons expressing p-cPLA2 might be the interneurons in vicinity of microglia as well as second order neurons receiving pain transmission from primary afferent neurons. Considering that iPLA2 also predominantly expresses in neurons [42, 43], and LPA can be synthesized and secreted by primary cultured neurons in vitro[44], we can hypothesize that spinal neurons, especially second order neurons and interneurons, are likely the cells responsible for the release of LPC/LPA, and the machineries may include the microglial activation.

It should be also noted that nerve injury-induced LPA production and increased PLA2 activities were completely absent in Lpar1 -/- and Lpar3 -/- mice, suggesting both LPA1 and LPA3 receptors were responsible for LPA synthesis, being consistent with the findings that both Lpar1 -/- and Lpar3 -/- mice abolished neuropathic pain behavior in response to LPA injection or nerve injury [20, 29]. On the other hand, our RT-PCR results and other reports demonstrated that both LPA1 and LPA3 receptors expressed in microglia [14, 45], while their levels in neurons were reported to be limited [13, 46], indicating that microglial LPA1 and LPA3 receptors might induce the release of biological factors, which in turn activated cPLA2 or iPLA2 in neurons, leading to an LPA production.

We found that both 18:1 and 20:4 LPA preferentially activated LPA1 and LPA3 receptors, while 16:0, 18:0 and 14:0 LPA were poor agonists, being consistent with previous reports [47]. Since the level of 20:4 LPA in the spinal dorsal horn was under detection limit, even after nerve injury in the present MALDI-TOFMS system, it was evident that 18:1 LPA is the most functionally potent LPA molecule, which was produced after nerve injury. On the other hand, we found that only 18:1 LPA, but not 16:0 or 18:0 LPA, produced new LPA with three species (18:1, 16:0 and 18:0 LPA) at 1-3 h, among which 18:1 LPA was also the predominant product. This result was consistent with the behavior finding that only 18:1 LPA, but not 16:0 or 18:0 LPA, induced neuropathic pain-like behavior. Given the fact that 18:1 LPA was the most potent molecule to interact with both LPA1 and LPA3 receptors, we can conclude that 18:1 LPA plays major roles in LPA1 and LPA3 receptors-mediated amplification of LPA production, possibly through microglial activation.

Conclusion

The present study demonstrates that 18:1 LPA is the major species of LPA in quantity and function in terms of LPA-induced amplification of LPA production. The mechanisms underlying the LPA production include the pain transmission by Glu and SP as well as indirect microglial activation, possibly through LPA1 and LPA3 receptors. The activation of cPLA2, which plays a key role for the production of LPC or LPA, is identified to be in neurons. Thus, produced LPA may work for the self-amplification via neuron-glia network. Targeted inhibition of 18:1 LPA or related pathways may be the potent strategy for the prevention of nerve injury-induced neuropathic pain.

Methods and materials

Animals

Male C57BL/6 J mice (TEXAM corporation, Nagasaki, Japan), homozygous mutant mice for the LPA1[48] and LPA3[49] receptor genes (Lpar1 -/- and Lpar3 -/- ), and their sibling wild-type mice from the same genetic background were used in this experiment. The subjects weighed 20-24 g. They were kept in a room maintained at 21 ± 2°C and 55 ± 5% relative humidity with a 12 h light/dark cycle, and had free access to a standard laboratory diet and tap water. The procedures were approved by the Nagasaki University Animal Care Committee, and complied with the fundamental guidelines for the proper conduct of animal experiments and related activities in academic research institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Drugs

18:1 LPA, MK-801 and minocycline were purchased from Sigma-Aldrich Co. (St. Louis, MO). 16:0, 17:0 and 18:0 LPA were purchased from Doosan Serdary Research Laboratories (Toronto, Canada). Monoisotopic 68Zn2+-Phos-tag (Phos-tag®) was obtained from the NARD Institute Ltd. (Hyogo, Japan) and MANAC Incorporated group (Hiroshima, Japan). CP-99994 was generously provided by Pfizer Pharmaceuticals (Sandwich, Kent, UK). AACOCF3 and BEL were purchased from Cayman Chemicals (Ann Arbor, MI).

For mass spectrometry experiments, various LPA species were dissolved in methanol (Sigma, St. Louis, MO). For in vivo experiments, all pharmacological antagonists except for minocycline were dissolved in artificial cerebrospinal fluid (125 mM NaCl, 3.8 mM KCl, 1.2 mM KH2PO4, 26 mM NaHCO3, 10 mM glucose). Minocycline was dissolved in physiological saline.

Partial sciatic nerve ligation

Partial ligation of the sciatic nerves was performed under anesthesia with pentobarbital (50 mg/kg, i.p.), according to modified methods [6, 30]. The common sciatic nerve of the right hind limb was exposed at the high thigh level through a small incision and the dorsal half of the nerve thickness was tightly ligated with a silk suture.

Extraction of LPA from tissues

The unilateral dorsal half including dorsal horn (laminae I-V) of the lumber (L4-L6) spinal cord was removed. The averaged wet weight of the isolated unilateral spinal cord in each mouse was approximately 6.15 mg tissue weight. LPA were extracted from tissues according to modified methods [7, 34]. After their isolation, the tissue samples were homogenized in 200 μl cold saline containing 100 mM of o-vanadate and 1 mM of EDTA. The homogenates were transferred into a glass tube (13 × 100 mm), and mixed with 0.5 nmol of 17:0 LPA, an internal standard, and 1 ml acetone. After vigorous vortex and centrifugation at 1300 × g for 5 min, the supernatant was discarded. The remaining pellet was washed twice with 0.5 ml acetone again, and dried with N2 gas. The dried pellet was mixed with 0.1 ml chloroform, 0.2 ml methanol and 0.08 ml water. After centrifugation at 1300 × g for 5 min, the supernatant was collected, and mixed with 0.2 ml chloroform, 0.2 ml 5% potassium chloride potassium chloride and 0.001 ml 28% aqueous ammonia. Following centrifugation at 1300 × g for 5 min, the supernatant was collected and washed with 0.4 ml chloroform/methanol (17:3, v/v). After washing for four times, 10 nmol of monoisotopic 68Zn2+-Phos-tag and 0.4 ml chloroform/methanol (17:3, v/v) were added to the supernatant (water/methanol phase). After shaking and centrifugation, the lower chloroform phase was collected, and the remaining water/methanol phase was extracted again. The combined chloroform phases were dried with N2 gas. The final sample was dissolved in 50 μl methanol containing 0.1% aqueous ammonia and stored at -20°C until use for analysis.

MALDI-TOFMS analyses

One μl from 50 μl of finally obtained methanol solution was spotted on an MALDI plate (Bruker Daltonics, Inc., CA, USA). Immediately, 1 μl of THAP solution (10 mg/ml in acetonitrile; Sigma, St. Louis, MO) was layered on the mixture as matrix solution. After drying, the sample was applied to an UltraflexTM TOF/TOF systems (Bruker Daltonics, Inc., CA, USA). Mass spectrometry was performed in the positive mode, using an accelerating voltage of 25 kV. The laser energy was used at energy of 30 – 70% (3.0 – 7.0 μJ) and a repetition rate of 10 Hz. The mass spectra were calibrated externally using Peptide calibration standard (Bruker Daltonics, Inc., CA, USA) as a standard peptide calibration. Each spectrum was produced by accumulating data of 1500 or 2500 consecutive laser shots.

Primary culture of mouse microglia

Glial cultures were prepared from the whole brain tissues of 1-day-old C57BL/6 J mice and maintained for 8–14 days in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (Gibco, Carlsbad, CA, USA), 1% penicillin/streptomycin (final concentration 100 units/ml; Invitrogen, Tokyo, Japan). All medium was changed every three days, from 24 h after the start of culture. The microglia was obtained as floating cells over the mixed glial culture, and seeded onto 6-well plate with the density of 1.0 × 105 cells/cm2. After incubation at 37°C in a 5% CO2 atmosphere overnight, we removed the medium and added 400 μl TRIzol (Invitrogen, Carlsbad, CA, USA) into each well for RT-PCR experiment.

RT-PCR

The expression levels of LPA receptors were evaluated by RT-PCR, according to described method [29, 50]. Cultured microglia and isolated L4-6 SC from naive mice were lysed with TRIzol for RNA preparation. Total RNA (1 μg/sample) was used for cDNA synthesis with PrimeScript® RT reagent Kit (Takara, Otsu, Japan). The cycling conditions for all primers were 3 min at 95°C, then 50 cycles of 30 s at 95°C, 30 s at 55°C and 2 min at 72°C. The PCR primer sequences were as follows: LPA1, 5’-ATCTTTGGCTATGTTCGCCA-3’ (forward) and 5’-TTGCTGTGAACTCCAGCCA-3’ (reverse); and for LPA3, 5’-TTGCCTCTGCAACATCTCGG-3’ (forward) and 5’-CATGACGGAGTTGAGCAGTG-3’ (reverse). Then, the PCR products were analyzed by 1.5% agarose gel electrophoresis.

Thermal paw withdrawal test

In this test, nociception was measured as the latency to paw withdrawal evoked by exposure to a thermal stimulus [6, 30, 51, 52]. Unanesthetized animals were placed in Plexiglas cages on top of a glass sheet and allowed an adaptation period of 1 h. A thermal stimulator (IITC Inc., Woodland Hills, CA) was positioned under the glass sheet and the focus of the projection bulb was aimed precisely at the middle of the plantar surface of the animal. A mirror attached to the stimulator permitted visualization of the plantar surface. A cut-off time of 20 s was set to prevent tissue damage.

Phospholipase A2 activity assays

The activities of cPLA2 and iPLA2 were detected using the following assays as described previously [6, 30, 53]. Briefly, ipsilateral side of spinal dorsal horn was removed. After sonication and centrifugation at 20000 × g for 20 min at 4°C, the supernatant was collected and kept on ice. The protein concentration of the supernatant was determined by the Lowry method, and the assays were performed using a cPLA2 assay kit (Cayman Chemicals, Ann Arbor, MI, USA) to evaluate the cPLA2 activity or a modified cPLA2 assay kit (Cayman Chemicals, Ann Arbor, MI, USA) to evaluate the iPLA2 activity, as described previously [53]. In the cPLA2 assay, the tissue samples were incubated with both BEL, an iPLA2 inhibitor [38], and a substrate, arachidonoyl thio-PC, at 20°C for 1 h in a assay buffer. The reactions were stopped by DTNB/EGTA for 5 min, and the absorbances were determined at 405 nm using a standard plate reader. To detect the activity of iPLA2, but not cPLA2, the samples were incubated with the substrate, arachidonoyl thio-PC, at 20°C for 1 h in a modified Ca2+-free buffer [4 mM EGTA, 160 mM HEPES pH 7.4, 300 mM NaCl, 8 mM Triton X-100, 60% glycerol, 2 mg/ml of bovine serum albumin (BSA)]. The reactions were stopped by the addition of 5,5’-dithiobis(nitrobenzoic acid) for 5 min. The activity of PLA2 was defined as the percentage of the control activity as follows: injured tissues (absorbance/mg of protein)/normal tissues (absorbance/mg of protein) × 100.

Phospholipase A1 activity assay

PLA1 activity assay was performed according to the manufacturer’s protocol of EnzChek® phospholipase A1 assay kit (Invitrogen, Molecular Probes, OR, USA). Briefly, isolated ipsilateral spinal dorsal horn was sonicated in PLA1 reaction buffer (50 mM Tris-HCl, 0.14 M NaCl, 2 mM CaCl2, pH 7.4) and centrifuged at 20000 × g for 20 min at 4°C. The supernatant was collected and its protein concentration was determined by the Lowry method. In the PLA1 assay, the substrate-liposome mix was prepared by mixing 9 μl of lipid mix [3 μl of dioleoylphosphatidylcholine (10 mM; Sigma-Aldrich, St. Louis, MO), 3 μl of dioleoylphosphatidylglycerol (10 mM; Sigma-Aldrich, St. Louis, MO) and 3 μl of PLA1 substrate (1 mM PED-A1; Invitrogen, Molecular Probes, OR, USA)] and 501 μl of PLA1 reaction buffer. Subsequently, 1 μl of tissue sample, standard PLA1 (Sigma-Aldrich, St. Louis, MO) or negative control (PLA1 reaction buffer) was incubated with 19 μl of substrate-liposome mix in a 384-well microplate (Greiner bio-one, Frickenhausen, Germany) for 30 min. Then the fluorescence was measured using a PHERAstar FS reader (BMG-Labtech, Offenburg, Germany) equipped for excitation at 485 nm and fluorescence emission at 520 nm. The activity of PLA1 was defined as the percentage of the control activity as follows: injured tissues (absorbance/mg of protein) / normal tissues (absorbance/mg of protein) × 100.

Immunohistochemistry

Mice were deeply anesthetized with pentobarbital (50 mg/kg) and perfused with potassium-free phosphate buffered saline (pH7.4), followed by 4% paraformaldehyde solution. L4-6 spinal cord segments were then isolated, postfixed in the same fixative for 3 h, and replaced with 25% sucrose overnight. Tissues were fast-frozen in cryo-embedding compound and cut on a cryostat at a thickness of 10 μm.

Immunofluorescence labeling was performed by blocking the sections with 2% BSA in TBST (0.1% Triton X-100 in Tris Buffered Saline) for 2 h at 20°C, followed by incubation with anti-NeuN antibody (1:500; anti-mouse, Chemicon, CA) or anti-Iba1 antibody (1:250; anti-goat, Abcam, Cambridge, UK) overnight at 4°C. After washing, sections were incubated with Alexa Fluor 594-conjugated anti-mouse IgG (1:300; Invitrogen, Carlsbad, CA) or Alexa Fluor 546-conjugated anti-goat IgG (1:300; Invitrogen, Carlsbad, CA), respectively, for 2 h at 20°C. Then, sections were blocked with 2% BSA in TBST for 2 h at 20°C and incubated overnight at 4°C with anti-phospho-cPLA2 antibody (anti-rabbit, 1:100; Abcam, Cambridge, UK). Sections were subsequently incubated with secondary antibody, Alexa Fluor 488-conjugated anti-rabbit IgG (1:300; Invitrogen, Carlsbad, CA), for 2 h at 20°C. Stained sections were washed and cover-slipped with Perma Fluor (Thermo Shandon, Pittsburgh, PA, USA). Images were collected using an LSM 710 confocal microscope with ZEN software (Carl Zeiss, Oberkochen, Germany).

Calcium mobilization assay

LPA1-B103 or LPA3-B103 cells were used for calcium mobilization assay. The cells were harvested by centrifugation and re-suspended with 0.1% BSA supplied-DMEM. The cell suspension was plated 30 μl per well in a 384-well plate with the density of 5.0 × 103 cells/well. Following incubation at 37°C in a 5% CO2 atmosphere overnight, cells were loaded with 10 μl Fluo-8 (8 μM) in 0.1% BSA supplied-DMEM containing 1 mg/ml amaranthl. After 30 min, 20 μl various LPA species at defined concentration was added, and fluorescence was recorded by Functional Drug Screening System/μCell (Hamamatsu Photonics K.K., Hamamatsu city, Japan) immediately. The fluorescence intensity was described as signal ratio (tested value / basal value).

Statistical analysis

Statistical analysis was evaluated using the Tukey’s multiple comparison post hoc analysis following one-way ANOVA. The criterion of significance was set at p < 0.05. All results are expressed as mean ± SEM.

Notes

Abbreviations

LPA: 

Lysophosphatidic acid

i.t.: 

Intrathecal

Lpar1-/- or Lpar3-/-: 

Lpar1- or Lpar3-deficient mice

LPC: 

Lysophosphatidylcholine

MALDI-TOFMS: 

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

Glu: 

Glutamate

SP: 

Substance P

NK1: 

Neurokinin 1

cPLA2: 

Cytosolic phospholipase A2

iPLA2: 

Calcium-independent phospholipase A2

PC: 

Phosphatidylcholine

AACOCF3: 

Arachidonyl trifluoromethyl ketone

BEL: 

Bromoenol lactone

i.p.: 

Intraperitoneal

PLA1: 

Phospholipase A1

RT-PCR: 

Reverse transcription polymerase chain reaction

NeuN: 

Neuronal nuclei

Iba1: 

Ionized calcium-binding adaptor molecule 1

p-cPLA2: 

Phosphorylated cPLA2

LPA1-B103 or LPA3-B103: 

B103 cells expressing LPA1 or LPA3 receptor

ED50: 

Half-maximal effective dose

DMEM: 

Dulbecco’s modified Eagle’s medium

BSA: 

bovine serum albumin

TBST: 

0.1% Triton X-100 in Tris Buffered Saline.

Declarations

Acknowledgments

We thank Ayaka Shinagawa and Yutaka Miura for technical helps. We appreciate Prof. Takao Shimizu for providing the B103 cells expressing LPA1 or LPA3 receptor. This study was supported by Grant-in-Aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) (23116513 to H.U.), a foreign researcher grant from Japan Society For The Promotion Of Science (JSPS; P11112 to L.M.), Grant-in-Aid for Young Scientists (B) (24790576 to J.N.), Ministry of Health, Labour and Welfare, the Tokyo Biomedical Research Foundation (2011 to H.U.), Ono Pharmaceutical Company Ltd and Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Authors’ Affiliations

(1)
Department of Molecular Pharmacology and Neuroscience, Nagasaki University Graduate School of Biomedical Sciences
(2)
Department of Molecular Biology, Dorris Neuroscience Center, The Scripps Research Institute

References

  1. Chan LC, Peters W, Xu Y, Chun J, Farese RV Jr, Cases S: LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA). J Leukoc Biol 2007, 82(5):1193–1200.View ArticlePubMedGoogle Scholar
  2. Zhao Y, Natarajan V: Lysophosphatidic acid (LPA) and its receptors: Role in airway inflammation and remodeling. Biochimica et Biophysica Acta (BBA) - Molec Cell Bio Lipids 2013, 1831(1):86–92.View ArticleGoogle Scholar
  3. Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A: Lysophosphatidic acid, a growth factor-like lipid, in the saliva. J Lipid Res 2002, 43(12):2049–2055.View ArticlePubMedGoogle Scholar
  4. Tokumura A, Miyake M, Nishioka Y, Yamano S, Aono T, Fukuzawa K: Production of Lysophosphatidic Acids by Lysophospholipase D in Human Follicular Fluids of In Vitro Fertilization Patients. Biol Reprod 1999, 61(1):195–199.View ArticlePubMedGoogle Scholar
  5. Aoki J, Taira A, Takanezawa Y, Kishi Y, Hama K, Kishimoto T, Mizuno K, Saku K, Taguchi R, Arai H: Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem 2002, 277(50):48737–48744.View ArticlePubMedGoogle Scholar
  6. Ma L, Uchida H, Nagai J, Inoue M, Aoki J, Ueda H: Evidence for De Novo Synthesis of Lysophosphatidic Acid in the Spinal Cord through Phospholipase A2 and Autotaxin in Nerve Injury-induced Neuropathic Pain. J Pharmacol Exp Ther 2010, 333(2):540–546.View ArticlePubMedGoogle Scholar
  7. Morishige J-i, Urikura M, Takagi H, Hirano K, Koike T, Tanaka T, Satouchi K: A clean-up technology for the simultaneous determination of lysophosphatidic acid and sphingosine-1-phosphate by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using a phosphate-capture molecule, Phos-tag. Rapid Commun Mass Spectrom 2010, 24(7):1075–1084.View ArticlePubMedGoogle Scholar
  8. Balazs L, Okolicany J, Ferrebee M, Tolley B, Tigyi G: Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am J Physiol Regul Integr Comp Physiol 2001, 280(2):R466-R472.PubMedGoogle Scholar
  9. Mills GB, Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003, 3(8):582–591.View ArticlePubMedGoogle Scholar
  10. Ye X, Hama K, Contos JJA, Anliker B, Inoue A, Skinner MK, Suzuki H, Amano T, Kennedy G, Arai H, et al.: LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 2005, 435(7038):104–108.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Pasternack SM, von Kugelgen I, Aboud KA, Lee Y-A, Ruschendorf F, Voss K, Hillmer AM, Molderings GJ, Franz T, Ramirez A, et al.: G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet 2008, 40(3):329–334.View ArticlePubMedGoogle Scholar
  12. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, Polosukhin V, Wain J, Karimi-Shah BA, Kim ND, et al.: The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008, 14(1):45–54.View ArticlePubMedGoogle Scholar
  13. Choi JW, Chun J: Lysophospholipids and their receptors in the central nervous system. Biochimica et Biophysica Acta (BBA) - Molec Cell Bio Lipids 2013, 1831(1):20–32.View ArticleGoogle Scholar
  14. Choi JW, Herr DR, Noguchi K, Yung YC, Lee C-W, Mutoh T, Lin M-E, Teo ST, Park KE, Mosley AN, et al.: LPA Receptors: Subtypes and Biological Actions. Annu Rev Pharmacol Toxicol 2010, 50(1):157–186.View ArticlePubMedGoogle Scholar
  15. Ueda H, Ueda M: Lysophosphatidic acid as an initiator of neuropathic pain: biosynthesis and demyelination. Clinical Lipidology 2011, 6(2):147–158.View ArticleGoogle Scholar
  16. Ueda H: Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol Ther 2006, 109(1–2):57–77.View ArticlePubMedGoogle Scholar
  17. Ueda H: Peripheral mechanisms of neuropathic pain - involvement of lysophosphatidic acid receptor-mediated demyelination. Mol Pain 2008, 4: 11.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Ueda H, Matsunaga H, Olaposi OI, Nagai J: Lysophosphatidic acid: Chemical signature of neuropathic pain. Biochimica et Biophysica Acta (BBA) - Molec Cell Bio Lipids 2013, 1831(1):61–73.View ArticleGoogle Scholar
  19. Xie W, Matsumoto M, Chun J, Ueda H: Involvement of LPA1 receptor signaling in the reorganization of spinal input through Abeta-fibers in mice with partial sciatic nerve injury. Mol Pain 2008, 4: 46.PubMed CentralView ArticlePubMedGoogle Scholar
  20. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H: Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 2004, 10(7):712–718.View ArticlePubMedGoogle Scholar
  21. Ma L, Matsumoto M, Xie W, Inoue M, Ueda H: Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a lysophosphatidic acid 1 receptor antagonist. J Neurochem 2009, 109(2):603–610.View ArticlePubMedGoogle Scholar
  22. Fujita R, Kiguchi N, Ueda H: LPA-mediated demyelination in ex vivo culture of dorsal root. Neurochem Int 2007, 50(2):351–355.View ArticlePubMedGoogle Scholar
  23. Nagai J, Uchida H, Matsushita Y, Yano R, Ueda M, Niwa M, Aoki J, Chun J, Ueda H: Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine. Mol Pain 2010, 6: 78.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Uchida H, Matsumoto M, Ueda H: Profiling of BoNT/C3-reversible gene expression induced by lysophosphatidic acid: ephrinB1 gene up-regulation underlying neuropathic hyperalgesia and allodynia. Neurochem Int 2009, 54(3–4):215–221.View ArticlePubMedGoogle Scholar
  25. Xie W, Uchida H, Nagai J, Ueda M, Chun J, Ueda H: Calpain-mediated down-regulation of myelin-associated glycoprotein in lysophosphatidic acid-induced neuropathic pain. J Neurochem 2010, 113(4):1002–1011.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Kashimoto R, Yamanaka H, Kobayashi K, Okubo M, Yagi H, Mimura O, Noguchi K: Phosphorylation of ezrin/radixin/moesin (ERM) protein in spinal microglia following peripheral nerve injury and lysophosphatidic acid administration. Glia 2013, 61(3):338–348.View ArticlePubMedGoogle Scholar
  27. Sun L, Wu Z, Hayashi Y, Peters C, Tsuda M, Inoue K, Nakanishi H: Microglial Cathepsin B Contributes to the Initiation of Peripheral Inflammation-Induced Chronic Pain. J Neurosci 2012, 32(33):11330–11342.View ArticlePubMedGoogle Scholar
  28. Ahn DK, Lee SY, Han SR, Ju JS, Yang GY, Lee MK, Youn DH, Bae YC: Intratrigeminal ganglionic injection of LPA causes neuropathic pain-like behavior and demyelination in rats. Pain 2009, 146(1–2):114–120.View ArticlePubMedGoogle Scholar
  29. Ma L, Uchida H, Nagai J, Inoue M, Chun J, Aoki J, Ueda H: Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain. Mol Pain 2009, 5(1):64.PubMed CentralView ArticlePubMedGoogle Scholar
  30. Ma L, Nagai J, Ueda H: Microglial activation mediates de novo lysophosphatidic acid production in a model of neuropathic pain. J Neurochem 2010, 115(3):643–653.View ArticlePubMedGoogle Scholar
  31. Nagai J, Ueda H: Pre-emptive morphine treatment abolishes nerve injury-induced lysophospholipid synthesis in mass spectrometrical analysis. J Neurochem 2011, 118(2):256–265.View ArticlePubMedGoogle Scholar
  32. Guenin E, Lecouvey M, Hardouin J: Could a nano-assisted laser desorption/ionization target improve the study of small organic molecules by laser desorption/ionization time-of-flight mass spectrometry? Rapid Commun Mass Spectrom 2009, 23(9):1395–1400.View ArticlePubMedGoogle Scholar
  33. Takeda H, Kawasaki A, Takahashi M, Yamada A, Koike T: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of phosphorylated compounds using a novel phosphate capture molecule. Rapid Commun Mass Spectrom 2003, 17(18):2075–2081.View ArticlePubMedGoogle Scholar
  34. Tanaka T, Tsutsui H, Hirano K, Koike T, Tokumura A, Satouchi K: Quantitative analysis of lysophosphatidic acid by time-of-flight mass spectrometry using a phosphate-capture molecule. J Lipid Res 2004, 45(11):2145–2150.View ArticlePubMedGoogle Scholar
  35. Inoue M, Ma L, Aoki J, Ueda H: Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX-mediated conversion to LPA, an initiator of neuropathic pain. J Neurochem 2008, 107(6):1556–1565.View ArticlePubMedGoogle Scholar
  36. Aoki J: Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 2004, 15(5):477–489.View ArticlePubMedGoogle Scholar
  37. Aoki J, Inoue A, Okudaira S: Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 2008, 1781(9):513–518.View ArticlePubMedGoogle Scholar
  38. Ackermann EJ, Conde-Frieboes K, Dennis EA: Inhibition of macrophage Ca(2+)-independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J Biol Chem 1995, 270(1):445–450.View ArticlePubMedGoogle Scholar
  39. Street IP, Lin HK, Laliberte F, Ghomashchi F, Wang Z, Perrier H, Tremblay NM, Huang Z, Weech PK, Gelb MH: Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2. Biochemistry 1993, 32(23):5935–5940.View ArticlePubMedGoogle Scholar
  40. Nishimasu H, Okudaira S, Hama K, Mihara E, Dohmae N, Inoue A, Ishitani R, Takagi J, Aoki J, Nureki O: Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat Struct Mol Biol 2011, 18(2):205–212.View ArticlePubMedGoogle Scholar
  41. Hanada M, Sugiura Y, Shinjo R, Masaki N, Imagama S, Ishiguro N, Matsuyama Y, Setou M: Spatiotemporal alteration of phospholipids and prostaglandins in a rat model of spinal cord injury. Anal Bioanal Chem 2012, 403(7):1873–1884.View ArticlePubMedGoogle Scholar
  42. Ong WY, Yeo JF, Ling SF, Farooqui AA: Distribution of calcium-independent phospholipase A2 (iPLA 2) in monkey brain. J Neurocytol 2005, 34(6):447–458.View ArticlePubMedGoogle Scholar
  43. Kurusu S, Matsui K, Watanabe T, Tsunou T, Kawaminami M: The Cytotoxic Effect of Bromoenol Lactone, a Calcium-independent Phospholipase A2 Inhibitor, on Rat Cortical Neurons in Culture. Cell Mol Neurobiol 2008, 28(8):1109–1118.View ArticlePubMedGoogle Scholar
  44. Fukushima N, Weiner JA, Chun J: Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology. Dev Biol 2000, 228(1):6–18.View ArticlePubMedGoogle Scholar
  45. Noguchi K, Herr D, Mutoh T, Chun J: Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 2009, 9(1):15–23.View ArticlePubMedGoogle Scholar
  46. Goldshmit Y, Munro K, Leong SY, Pebay A, Turnley AM: LPA receptor expression in the central nervous system in health and following injury. Cell Tissue Res 2010, 341(1):23–32.View ArticlePubMedGoogle Scholar
  47. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K: Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett 2000, 478(1–2):159–165.View ArticlePubMedGoogle Scholar
  48. Contos JJA, Fukushima N, Weiner JA, Kaushal D, Chun J: Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci 2000, 97(24):13384–13389.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Contos JJA, Chun J: The mouse lpA3/Edg7 lysophosphatidic acid receptor gene: genomic structure, chromosomal localization, and expression pattern. Gene 2001, 267(2):243–253.View ArticlePubMedGoogle Scholar
  50. Fujita R, Ma Y, Ueda H: Lysophosphatidic acid-induced membrane ruffling and brain-derived neurotrophic factor gene expression are mediated by ATP release in primary microglia. J Neurochem 2008, 107(1):152–160.View ArticlePubMedGoogle Scholar
  51. Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32(1):77–88.View ArticlePubMedGoogle Scholar
  52. Ma L, Nagai J, Sekino Y, Goto Y, Nakahira S, Ueda H: Single application of A2 NTX, a botulinum toxin A2 subunit, prevents chronic pain over long periods in both diabetic and spinal cord injury-induced neuropathic pain models. J Pharmacol Sci 2012, 119(3):282–286.View ArticlePubMedGoogle Scholar
  53. Smani T, Zakharov SI, Leno E, Csutora P, Trepakova ES, Bolotina VM: Ca2 + -independent phospholipase A2 is a novel determinant of store-operated Ca2+ entry. J Biol Chem 2003, 278(14):11909–11915.View ArticlePubMedGoogle Scholar

Copyright

© Ma et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement